Eli Lilly and Co

Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court
Health

Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court

Chief Executive Officers of pharmaceutical companies testify before the Senate Finance Committee on “Drug Pricing in America: A Prescription for Change, Part II” February 26, 2019 in Washington, DC. From left to right are Richard A. Gonzalez, chairman and CEO of AbbVie Inc; Pascal Soriot, executive director and CEO of AstraZeneca; Giovanni Caforio, chairman of […]

Read More
Credit Suisse sees Eli Lilly headed higher as Mounjaro users espouse weight loss drug on social media
Health

Credit Suisse sees Eli Lilly headed higher as Mounjaro users espouse weight loss drug on social media

You can’t deny the buzz. Credit Suisse analyst Trung Huynh has combed through social media and is impressed by the awareness — and demand — for GLP-1 medications such as Eli Lilly ‘s Mounjaro. “Although we caution posts may have responder bias, and comments are in the public domain and unconfirmed, nonetheless we have parsed […]

Read More
Eli Lilly CEO says Medicare price negotiations could harm drug development
Health

Eli Lilly CEO says Medicare price negotiations could harm drug development

David Ricks, CEO, Eli Lilly. Scott Mlyn | CNBC Eli Lilly CEO David Ricks on Tuesday said Medicare price negotiations, which aim to cut costs for older Americans, could potentially harm drug development.  “I’m really worried about the harm this will do to new cures and possibilities in medicine,” Ricks said in an interview on […]

Read More
Nvidia stole the earnings highlight last week. This week, it is really all about the credit card debt ceiling
World

Nvidia stole the earnings highlight last week. This week, it is really all about the credit card debt ceiling

As has been the circumstance for most of the calendar year, final week’s equities story centered all-around the tech-significant Nasdaq Composite , which rallied Thursday and Friday on the again of Club keeping Nvidia ‘s (NVDA) stand-out earnings report. In addition to beating on income and income, the chipmaker unveiled a jaw-dropping forecast for its […]

Read More
ASCO conference will put the focus on the fight against cancer. These stocks are in the spotlight
Health

ASCO conference will put the focus on the fight against cancer. These stocks are in the spotlight

Developments in cancer research will be in the spotlight as the American Society of Clinical Oncology hosts the world’s biggest cancer research conference in Chicago, starting Thursday. Investors have already caught a glimpse of the topics that will be discussed but many are eager to hear the details behind the abstracts, and no doubt there […]

Read More
We’re starting a new position in one of the Big 3 global medical imaging and diagnostics companies
Health

We’re starting a new position in one of the Big 3 global medical imaging and diagnostics companies

This company operates in an $84 billion total addressable market that the company sees growing to around $100 billion by 2024. Source

Read More
Oppenheimer says investors are missing opportunities in three biotech areas and the related stocks
Health

Oppenheimer says investors are missing opportunities in three biotech areas and the related stocks

As biopharma investors follow the latest buzz around advancements in clinical research, they may be under-appreciating opportunities in neurology, psychiatry and genetic medicine, according to a report from Oppenheimer. Specifically, analyst Jay Olson called out companies such as Biogen , Karuna Therapeutics and Crispr Therapeutics , among others. “Our analysis shows Genetic Medicine and Metabolic […]

Read More
Alzheimer’s treatment Leqembi could cost Medicare up to  billion per year, study estimates
Business

Alzheimer’s treatment Leqembi could cost Medicare up to $5 billion per year, study estimates

The Alzheimer’s drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai | Reuters The new Alzheimer’s antibody treatment Leqembi could cost Medicare up to $5 billion per year, according to research published in a leading medical journal this week. Medicare would spend about $2 billion per year […]

Read More
Eli Lilly CEO vows not to raise insulin prices again, while Novo Nordisk and Sanofi hedge
Health

Eli Lilly CEO vows not to raise insulin prices again, while Novo Nordisk and Sanofi hedge

Eli Lilly CEO Dave Ricks on Wednesday promised not to raise prices on the company’s existing insulin products again — the only executive to do so before a Senate Health Committee hearing on making the life-saving diabetes drug more affordable. Sen. Bernie Sanders, the committee’s chair, asked Ricks and the CEOs of Novo Nordisk and […]

Read More
FDA commissioner praises Eli Lilly Alzheimer’s treatment results
Health

FDA commissioner praises Eli Lilly Alzheimer’s treatment results

FDA Commissioner Dr. Robert Califf speaks at an event celebrating hearing aids being available over the counter at a Walgreens in Washington, D.C., Oct. 19, 2022. Nathan Posner | Anadolu Agency | Getty Images Food and Drug Commissioner Dr. Robert Califf praised results Eli Lilly announced Wednesday that a clinical trial showed its Alzheimer’s treatment […]

Read More